

**From:** Emma Rosser <pharma@smiconferences.co.uk>  
**To:** Kester, Tonykester@aging.sc.gov  
**Date:** 12/13/2016 7:10:14 AM  
**Subject:** RNA Therapeutics | Ensuring Commercial Success and Clinical Viability

---

## RNA Therapeutics 2017

8th Annual Conference: 22nd & 23rd February | Interactive Workshop: 21st February  
Cophthorne Tara Hotel, London, UK | Proudly Sponsored by: Lipocalyx

[Download a brochure here](#)

Dear Mr Tony Kester,

This is your last chance to secure an **earlybird rate** at the only conference in the market which will provide updates on recent scientific research and industry led case studies from those driving medical progress in **RNA Therapeutics**.

---

### ABOUT THE CONFERENCE:

---

With the need for optimised bioavailability and kinetics, RNA based therapeutics is a promising class of treatment for a number of chronic and rare diseases. However challenges in targeted delivery and toxicity remain.

Commercial success and clinical viability is requested at every level making **RNA Therapeutics** the perfect platform to strengthen knowledge in key topics such as **manufacturing, drug formulation, patent protection** and **medical trials**, whilst looking at the practicalities of clinical application and keeping attendees informed of emerging technology.

Aimed at an audience of Senior Scientists and Heads of Drug Delivery, the **8th annual RNA Therapeutics conference** will discuss the latest industry advancements, welcoming regulatory guidance from the **MHRA** and expertise from the likes of **GSK, Roche, AstraZeneca** and **Novartis**.

[View more information](#)

---

### FEATURED SPEAKERS:

---

- Nagy Habib, Head of Surgery, Co-Founder, Imperial College Healthcare NHS Trust, **MiNA Therapeutics**
- Heinrich Haas, Vice President RNA Formulation & Drug Delivery, **BioNTech RNA Pharmaceuticals**
- Bo Rode Hansen, Global Head of RNA Therapeutics, **Roche**
- John Johnston, Clinical Assessor Biologicals & Biotechnology Unit, **MHRA**
- Nicole Meisner-Kober, Senior Investigator, RNA Biology, **Novartis Institutes for Biomedical Research**
- Jeffrey Ulmer, Head of Pre-Clinical Research & Development, **GSK Vaccines USA**
- David Giljohann, CEO, **Exicure**
- Shai Erlich, Chief Medical Officer & President USA, Quark Pharmaceuticals Inc
- Amotz Shemi, CEO, **Silenseed**
- Sanyogitta Puri, Associate Principal Scientist, **AstraZeneca**

[See the full speaker line-up](#)

---

**GET INVOLVED:**

---

**£100 earlybird saving ends 16th December**

[Sign up here](#)

For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6168 or email [amalick@smi-online.co.uk](mailto:amalick@smi-online.co.uk)

For delegate enquiries contact Fateja Begum on +44 (0)20 7827 6184 or email [fbegum@smi-online.co.uk](mailto:fbegum@smi-online.co.uk)

We hope you are able to join us for what promises to be another engaging and insightful show next February and would like to take this opportunity in wishing you a Merry Christmas and Happy New Year.

Kind Regards,

The SMi Pharmaceutical Team

[www.therapeutics-rna.com](http://www.therapeutics-rna.com)

You are registered as: [kester@aging.sc.gov](mailto:kester@aging.sc.gov) Your Unique Reference Number: 92804565  
To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>